Tags

Type your tag names separated by a space and hit enter

Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis.
Clin Infect Dis. 2009 Dec 01; 49(11):1660-6.CI

Abstract

BACKGROUND

Although the DNA of parvovirus B19 (B19V) is frequently detected in patients with dilated cardiomyopathy or myocarditis, whether the parvovirus causes disease is questionable, since even in healthy individuals the virus persists in various tissues. The same question applies to human bocavirus (HBoV). We have determined the prevalence and quantity of B19V and HBoV DNA in heart tissue of patients who were not experiencing virus-related heart diseases and analyzed whether the seroprevalence corresponded to DNA prevalence in the heart.

METHODS

Samples of left-atrium heart tissue and serum were obtained from 100 patients who underwent open-heart surgery. Serum immunoglobulin (Ig) G and IgM against proteins encoded by B19V and HBoV were detected by enzyme-linked immunoabsorption assay and immunoblotting. B19V and HBoV DNA concentrations were determined by quantitative real-time polymerase chain reaction (PCR) in heart tissue and serum samples. Nested PCRs for VP1, K71, and GT3 identified the B19V genotypes.

RESULTS

The prevalences of serum IgG specific for B19V and HBoV were 85% and 96%, respectively. Of all the patients, 85% had B19V DNA detected in heart tissues, and 4% displayed low-level B19V viremia, whereas only 5% of heart tissue samples and none of the serum samples demonstrated HBoV DNA. The sensitivity of B19V serological testing for B19V DNA in heart samples was 0.96 (95% confidence interval, 0.92-1.0). Specificity was 0.8 (95% confidence interval, 0.6-1.0), and the positive predictive value was 0.96 (95% confidence interval, 0.92-1.0). B19V genotypes 1 and 2 were present in 11% and 89% of heart tissues samples, respectively. B19V genotype 3 was not detected in any of the samples.

CONCLUSIONS

Our data suggest that B19V but not HBoV demonstrates a lifelong persistence in the heart. The detection of B19V DNA in heart tissue showed no correlation with clinical symptoms. We strongly recommend that serological testing become a standardized procedure for future studies, to obtain representative data concerning the prevalence of B19V in the heart.

Authors+Show Affiliations

Department of Medicine, University of Dresden, Dresden, Germany. Friedhelm.Kuethe@uniklinikum-dresden.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19863443

Citation

Kuethe, Friedhelm, et al. "Prevalence of Parvovirus B19 and Human Bocavirus DNA in the Heart of Patients With No Evidence of Dilated Cardiomyopathy or Myocarditis." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 49, no. 11, 2009, pp. 1660-6.
Kuethe F, Lindner J, Matschke K, et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis. 2009;49(11):1660-6.
Kuethe, F., Lindner, J., Matschke, K., Wenzel, J. J., Norja, P., Ploetze, K., Schaal, S., Kamvissi, V., Bornstein, S. R., Schwanebeck, U., & Modrow, S. (2009). Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 49(11), 1660-6. https://doi.org/10.1086/648074
Kuethe F, et al. Prevalence of Parvovirus B19 and Human Bocavirus DNA in the Heart of Patients With No Evidence of Dilated Cardiomyopathy or Myocarditis. Clin Infect Dis. 2009 Dec 1;49(11):1660-6. PubMed PMID: 19863443.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. AU - Kuethe,Friedhelm, AU - Lindner,Juha, AU - Matschke,Klaus, AU - Wenzel,Juergen J, AU - Norja,Päivi, AU - Ploetze,Katrin, AU - Schaal,Sarah, AU - Kamvissi,Virginia, AU - Bornstein,Stefan R, AU - Schwanebeck,Uta, AU - Modrow,Susanne, PY - 2009/10/30/entrez PY - 2009/10/30/pubmed PY - 2010/1/27/medline SP - 1660 EP - 6 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 49 IS - 11 N2 - BACKGROUND: Although the DNA of parvovirus B19 (B19V) is frequently detected in patients with dilated cardiomyopathy or myocarditis, whether the parvovirus causes disease is questionable, since even in healthy individuals the virus persists in various tissues. The same question applies to human bocavirus (HBoV). We have determined the prevalence and quantity of B19V and HBoV DNA in heart tissue of patients who were not experiencing virus-related heart diseases and analyzed whether the seroprevalence corresponded to DNA prevalence in the heart. METHODS: Samples of left-atrium heart tissue and serum were obtained from 100 patients who underwent open-heart surgery. Serum immunoglobulin (Ig) G and IgM against proteins encoded by B19V and HBoV were detected by enzyme-linked immunoabsorption assay and immunoblotting. B19V and HBoV DNA concentrations were determined by quantitative real-time polymerase chain reaction (PCR) in heart tissue and serum samples. Nested PCRs for VP1, K71, and GT3 identified the B19V genotypes. RESULTS: The prevalences of serum IgG specific for B19V and HBoV were 85% and 96%, respectively. Of all the patients, 85% had B19V DNA detected in heart tissues, and 4% displayed low-level B19V viremia, whereas only 5% of heart tissue samples and none of the serum samples demonstrated HBoV DNA. The sensitivity of B19V serological testing for B19V DNA in heart samples was 0.96 (95% confidence interval, 0.92-1.0). Specificity was 0.8 (95% confidence interval, 0.6-1.0), and the positive predictive value was 0.96 (95% confidence interval, 0.92-1.0). B19V genotypes 1 and 2 were present in 11% and 89% of heart tissues samples, respectively. B19V genotype 3 was not detected in any of the samples. CONCLUSIONS: Our data suggest that B19V but not HBoV demonstrates a lifelong persistence in the heart. The detection of B19V DNA in heart tissue showed no correlation with clinical symptoms. We strongly recommend that serological testing become a standardized procedure for future studies, to obtain representative data concerning the prevalence of B19V in the heart. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/19863443/Prevalence_of_parvovirus_B19_and_human_bocavirus_DNA_in_the_heart_of_patients_with_no_evidence_of_dilated_cardiomyopathy_or_myocarditis_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/648074 DB - PRIME DP - Unbound Medicine ER -